HIV Protease antibody

Antigen: HIV Protease

Clonality: Monoclonal (1696)

Host: Mouse

Application: Western Blotting (WB), Functional Studies (Func), ELISA

Catalog no.: ABIN94325

Additional Information

Immunogen: Bacterially expressed full-length HIV-1 protease

Format: Purified

Isotype: IgG1  (Matching secondary antibodies)

Clone: 1696

Description: The HIV protease (PR) hydrolyzes polyproteins of HIV virus into functional protein productsthat are essential for its assembly and subsequent activity. This maturation process occursas the virion buds from the host cell.HIV protease inhibitors are used in the treatment of patients with AIDS and were consideredthe first breakthrough in over a decade of AIDS research. HIV protease inhibitors can lowerthe viral load carried by AIDS patents.

Specificity: The antibody 1696 recognizes free N-terminus of mature HIV protease (HIV-1 and HIV-2),an enzyme that hydrolyzes polyproteins of HIV viruses into functional proteins.The antibody 1696 does not react with the precursor.

Application Details

Application Notes: Western Blotting - Recommended dilution: 0.5 µg/ml. Sample preparation: Resuspend approx. 50 mil. cells in 1 ml cold Lysis buffer (1%laurylmaltoside in 20 mM Tris/Cl, 100 mM NaCl pH 8. 2, 50 mM NaF including Proteaseinhibitor Cocktail). Incubate 60 min on ice. Centrifuge to remove cell debris. Mix lysate withreducing Laemmli SDS-PAGE sample buffer. Application note: Reducing conditions. Functional Application: The antibody 1696 strongly inhibits the enzyme activity of HIV-1 and HIV-2 proteases.

Concentration: 1 mg/ml

Purity: > 95% (by SDS-PAGE)

Purification: Purified from ascites by protein-A affinity chromatography.

Buffer: Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4

Storage: Store at 2-8 o C. Do not use after expiration date stamped on vial label. For long-term storage aliquot and store at -20 o C. Avoid freeze/thaw cycles.

Research Area: Virology, Proteases

Restrictions: For Research Use only

Images

Dot Blot

Publications

Publications: Hallenga: "Increased expression and immunogenicity of HIV-1 protease following inactivation of the enzymatic activity." in: Vaccine, 2010 (PubMed).